Publication

Light-controlled inhibition of BRAFV600E kinase

Hoorens, M. W. H., Ourailidou, M. E., Rodat, T., van der Wouden, P. E., Kobauri, P., Kriegs, M., Peifer, C., Feringa, B. L., Dekker, F. J. & Szymanski, W., 1-Oct-2019, In : European Journal of Medicinal Chemistry. 179, p. 133-146 14 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard

Documents

  • Light-controlled inhibition of BRAFV600E kinase

    Final author's version, 1 MB, PDF document

    Embargo ends: 25/06/2021

    Request copy

  • Light-controlled inhibition of BRAFV600E kinase

    Final publisher's version, 2 MB, PDF document

    Request copy

DOI

Metastatic melanoma is amongst the most difficult types of cancer to treat, with current therapies mainly relying on the inhibition of the BRAFV600E mutant kinase. However, systemic inhibition of BRAF by small molecule drugs in cancer patients results - paradoxically - in increased wild-type BRAF activity in healthy tissue, causing side-effects and even the formation of new tumors. Here we show the development of BRAFV600E kinase inhibitors of which the activity can be switched on and off reversibly with light, offering the possibility to overcome problems of systemic drug activity by selectively activating the drug at the desired site of action. Based on a known inhibitor, eight photoswitchable effectors containing an azobenzene photoswitch were designed, synthesized and evaluated. The most promising inhibitor showed an approximately 10-fold increase in activity upon light-activation. This research offers inspiration for the development of therapies for metastatic melanoma in which tumor tissue is treated with an active BRAFV600E inhibitor with high spatial and temporal resolution, thus limiting the damage to other tissues.

Original languageEnglish
Pages (from-to)133-146
Number of pages14
JournalEuropean Journal of Medicinal Chemistry
Volume179
Publication statusPublished - 1-Oct-2019

View graph of relations

ID: 90022472